These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 31607390)

  • 21. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
    Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
    Dertschnig S; Gergely P; Finke J; Schanz U; Holler E; Holtick U; Socié G; Medinger M; Passweg J; Teshima T; Stylianou C; Oehen S; Heim D; Bucher C
    Transplant Cell Ther; 2023 Jan; 29(1):41.e1-41.e9. PubMed ID: 36343893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mobilized Multipotent Hematopoietic Progenitors Promote Expansion and Survival of Allogeneic Tregs and Protect Against Graft Versus Host Disease.
    D'Aveni M; Notarantonio AB; Agbogan VA; Bertrand A; Fouquet G; Gastineau P; Garfa-Traoré M; De Carvalho M; Hermine O; Rubio MT; Zavala F
    Front Immunol; 2020; 11():607180. PubMed ID: 33643294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges.
    Hefazi M; Bolivar-Wagers S; Blazar BR
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
    Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
    Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis.
    Troullioud Lucas AG; Lindemans CA; Bhoopalan SV; Dandis R; Prockop SE; Naik S; Keerthi D; de Koning C; Sharma A; Nierkens S; Boelens JJ
    Cytotherapy; 2023 Sep; 25(9):977-985. PubMed ID: 37330731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
    Zaghi E; Calvi M; Di Vito C; Mavilio D
    Front Immunol; 2019; 10():2794. PubMed ID: 31849972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4
    Mancusi A; Piccinelli S; Velardi A; Pierini A
    Front Immunol; 2019; 10():2901. PubMed ID: 31921162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of graft immune composition with outcomes after allogeneic stem cell transplantation: Moving towards a perfect transplant.
    Gu G; Yang JZ; Sun LX
    Cell Immunol; 2018 Jan; 323():1-8. PubMed ID: 29145997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.
    Roddie C; Peggs KS
    Expert Opin Biol Ther; 2011 Apr; 11(4):473-87. PubMed ID: 21269237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
    Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
    Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storb RF
    J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
    Jiang H; Fu D; Bidgoli A; Paczesny S
    Front Immunol; 2021; 12():761448. PubMed ID: 34675938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
    Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
    Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling the interaction between donor-derived regulatory T cells and effector T cells early after allogeneic hematopoietic stem cell transplantation.
    Nishiyama N; Ruoff P; Jimenez JC; Miwakeichi F; Nishiyama Y; Yata T
    Biosystems; 2023 May; 227-228():104889. PubMed ID: 37019377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Wang Y; Yan CH; Wang JZ; Zhang XH; Xu LP; Liu KY; Huang XJ
    Clin Transplant; 2014 Aug; 28(8):926-34. PubMed ID: 24931494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.